Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy

R. Buhl

ABSTRACT: The efficacy of omalizumab has been extensively investigated in clinical trials in patients with severe persistent allergic (pre-treatment total immunoglobulin E 30–700 IU·mL⁻¹) asthma including the Investigation of Omalizumab in Severe Asthma Treatment (INNOVATE) study, which enrolled patients with inadequately controlled severe persistent allergic asthma despite receiving high-dose inhaled corticosteroid in combination with a long-acting β₂-agonist, and also additional controller medication if required.

In the INNOVATE study, add-on omalizumab significantly reduced clinically significant exacerbation rates by 26% (0.68 versus 0.91), severe exacerbation rates by 50% (0.24 versus 0.48) and emergency visit rates by 44% (0.24 versus 0.43) and significantly improved asthma-related quality of life (QoL) compared with placebo. In a pooled analysis of data from seven studies, add-on omalizumab significantly reduced asthma exacerbation rates by 38% (0.91 versus 1.47) and total emergency visits by 47% (0.332 versus 0.623). In addition, omalizumab significantly improved QoL versus current asthma therapy in a pooled analysis of data from six studies.

Omalizumab has demonstrated a good safety and tolerability profile in completed phase-I, -II and -III studies involving >7,500 patients with asthma, rhinitis or related conditions. Omalizumab represents a major advance for the treatment of severe persistent allergic asthma that is inadequately controlled despite treatment with inhaled corticosteroids and a long-acting β₂-agonist.

KEYWORDS: Allergy, anti-immunoglobulin E, asthma, exacerbation, omalizumab, therapy
patients). Despite high levels of medication use, 67% were considered to be at high risk of asthma-related death (previous intubation or emergency room visit/hospitalisation in the previous year), asthma had a meaningful impact on patients’ quality of life (QoL) and an average of 31 school or work days had been missed in the previous year due to asthma.

The primary efficacy variable was the rate of clinically significant asthma exacerbations, defined as asthma worsening requiring treatment with systemic corticosteroids (SCS). Other outcome variables included: severe exacerbation rate (peak expiratory flow or forced expiratory volume in one second <60% of personal best and requiring SCS); emergency visit rate (hospital admissions, emergency department and unscheduled visits to the doctor); and asthma-related QoL, as assessed by the Asthma Quality of Life Questionnaire (AQLQ) [12].

In the INNOVATE trial, adding omalizumab to high-dose ICS in combination with a LABA significantly reduced the rate of clinically significant exacerbations by 26% versus add-on placebo (clinically significant exacerbation rate adjusted post hoc for an observed imbalance in exacerbation history, 0.68 versus 0.91, \( p=0.042 \); unadjusted result 19% reduction, 0.74 versus 0.92, \( p=0.153 \); fig. 2). Omalizumab significantly reduced severe exacerbation rate by 50% versus placebo (0.24 versus 0.48, \( p=0.002 \); fig. 2) and emergency visit rate by 44% versus placebo (0.24 versus 0.43, \( p=0.038 \); fig. 3). The number needed to treat with omalizumab in addition to GINA 2002 step 4 therapy to prevent one event per year above placebo was 2.7 for clinically significant exacerbations, 2.0 for severe exacerbations and 2.8 for total emergency visits (table 1) [13].

Importantly, add-on omalizumab treatment also provided significant QoL improvements for patients (fig. 4). Change from baseline in AQLQ overall score was 0.91 in omalizumab compared with 0.46 in the placebo group (\( p<0.001 \)). Significant (\( p<0.01 \)) improvements were seen in all individual domains. Significantly more patients taking omalizumab achieved clinically meaningful improvements in QoL compared with placebo (60.8 versus 47.8%; \( p=0.008 \)), equating to a \( \geq 0.5 \)-point improvement from baseline in AQLQ overall score measured across the domains of activity limitations, asthma symptoms, emotional function and environmental exposure.

### POOLED ANALYSIS

Efficacy was further assessed in an analysis of pooled data from seven clinical trials of omalizumab (including INNOVATE) carried out in patients with asthma [3]. The pooled analysis included 4,308 patients (2,511 patients received omalizumab), of which 93% had severe persistent asthma. Adding omalizumab to current asthma therapy in the larger pooled population from all seven studies consistently

**TABLE 1** Number needed to treat (NNT) with omalizumab in addition to step 4 therapy to prevent one event per year above placebo

| Efficacy outcome | NNT |
|-----------------|-----|
| Clinically significant exacerbation | 2.7 |
| Severe exacerbation | 2.0 |
| Emergency visit | 2.8 |

*Note: these are not all separate events. Data taken from [13].
confirmed the findings seen in INNOVATE. Add-on omalizumab significantly reduced asthma exacerbation rates by 38.3% versus control (0.91 \textit{versus} 1.47; \textit{p}<0.0001; table 2) and total emergency visits by 47% \textit{versus} control (0.332 \textit{versus} 0.623; \textit{p}<0.0001; table 3). In the pooled analysis, omalizumab significantly reduced each component of the composite total emergency visit rate. Hospital admissions were reduced by 51\% (\textit{p}=0.041), emergency room visits by 60\% (\textit{p}=0.013) and unscheduled doctor visits by 43\% (\textit{p}=0.0003; table 3).

In the pooled analysis, QoL was measured in five clinical trials in addition to INNOVATE, with 1,221 patients receiving omalizumab and 1,032 receiving placebo/control across the six studies [14]. Omalizumab consistently improved QoL, delivering significantly greater improvements in the AQLQ overall score compared with placebo/control (1.01 \textit{versus} 0.61; \textit{p}<0.0001) and in the proportion of patients in the pooled population recording a \text{\geq}0.5\text{-point improvement in AQLQ overall score (66.3\% omalizumab \textit{versus} 52.4\% placebo/control); \textit{p}<0.0001}.

SAFETY AND TOLERABILITY
The safety and tolerability profile of omalizumab was evaluated in an analysis of data from completed phase-I, -II and -III studies involving >7,500 adult and adolescent patients with asthma, rhinitis or related conditions [15]. Of these patients, >5,300 received omalizumab, including 3,700 with moderate-to-severe persistent asthma.

In all controlled studies (omalizumab: \textit{n}=3,678; control: \textit{n}=2,452), adverse events (AEs) were reported in 74.8\% of patients receiving omalizumab and in 75.2\% of patients in the control group. Serious AEs (i.e. events that were fatal or life threatening, required hospitalisation, were significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or were considered medically significant) were reported by 4.2\% of patients receiving omalizumab and by 3.8\% of patients in the control group. Nasopharyngitis, upper respiratory tract infection, headache and sinusitis were the most frequently reported AEs in the omalizumab and control groups (table 4). Any differences observed between the groups were small and not indicative of specific organ toxicity. AEs were generally of mild-to-moderate severity and of short duration. Severe AEs occurred more frequently in the control group than in the omalizumab group (12.6 \textit{versus} 10.8\%; table 5). Serious AEs occurred infrequently (omalizumab 4.5\%, control 3.8\%). Few patients discontinued due to AEs (omalizumab 2\%, control 1\%). In placebo-controlled allergic asthma studies, overall incidence of suspected drug-related AEs was similar in the omalizumab and placebo groups (9.2 \textit{versus} 7.6\%, respectively). Post-launch data in the USA (~40,000 patients) are consistent with omalizumab clinical trials data.
ADVERSE EVENTS OF SPECIAL INTEREST

The risk of specific hypothetical safety concerns that might be associated with a monoclonal antibody targeting an immune system mediator (e.g., hypersensitivity reactions, malignant neoplasia and parasitic infections) as well as regarding issues that were identified during pre-clinical investigation (thrombocytopenia) have also been assessed.

Hypersensitivity

As omalizumab is a protein, it might be expected to be associated with hypersensitivity reactions and related immunological effects. As residues of murine origin constitute <5% of the omalizumab molecule and omalizumab cannot cross-link high-affinity immunoglobulin (Ig)E receptors (FcεRI) and activate effector cells, omalizumab has low anaphylactogenic potential. None of the omalizumab-treated patients developed measurable anti-omalizumab antibodies. Skin rash (urticaria) is a common manifestation of allergic reactions. In phase-II and -III trials, the incidence of urticaria was similar in patients treated with omalizumab (1.1%) and control patients (1.2%), and the incidence of severe systemic hypersensitivity was 0.1% in both groups. As omalizumab is an Ig designed to bind to the patient’s IgE, there is a theoretical possibility of immune-complex-mediated AEs following administration. There has been no incidence of immune–complex disease in clinical trials with omalizumab.

Based on spontaneous reports and an estimated exposure of ~57,300 patients from June 2003 to December 2006 (USA), the frequency of anaphylaxis attributed to omalizumab use was estimated to be ≥0.2% of patients (United States Prescribing Information, July 2007). As a precaution, medications for the treatment of anaphylactic reactions should be available for immediate use following administration of omalizumab (European Union (EU) summary of product characteristics (SmPC)).

Malignancy

During the omalizumab clinical programme, a number of cancer cases were reported with a slight numerical imbalance between those arising in the omalizumab-treated group (25 cases; 0.5%) compared with the control group (5 cases; 0.18%). No cases of malignant neoplasia were considered to be drug-related by a panel of independent oncologists blinded to treatment assignment. An in-depth clinical and statistical analysis of malignant neoplasia reported in multiple-dose clinical studies of omalizumab of up to 4 yrs duration was conducted [16]. In addition, a literature review and a comparison of cancer rates with the National Institutes of Health (NIH) Surveillance, Epidemiology, and End Results (SEER) database were undertaken.

The malignancy rate per 1,000 patient-yrs in the omalizumab group was comparable with the control group (p>0.5). The range of relative risk estimates across omalizumab phase I–III clinical trials (0.75–5.14) was consistent with estimates for asthmatic populations reported in the literature (0.75–2.1). A meta-analysis of five cohort studies in asthmatic populations [17–21] found no association between asthma and cancer rates (incidence ratio (95% confidence interval) 0.95 (0.69–1.30)), suggesting that asthma is neither a risk factor nor a protective factor for cancer. A comparison of cancer rates (from the clinical programme) with the NIH SEER database found that the standardised incidence ratio (SIR) of observed/expected number of events (malignant neoplasia) in the omalizumab group was 0.99 (0.55–1.63), i.e. near identical to that expected in the general population, whereas the control group SIR was one-third of that expected (0.31 (0.04–1.11)). Over time and with increased exposure (sample size and duration) the SIR for the omalizumab-treated group has decreased from the 1.3 (0.69–2.33) value at the time of Food and Drug Administration submission in June 2003.

Overall, clinical data do not suggest a causal link between omalizumab and cancer. A 5-yr post-marketing surveillance study (the EXCELS study: an epidemiological study of Xolair® (omalizumab): evaluating clinical effectiveness and long-term safety in patients with moderate-to-severe asthma) involving 7,500 patients is ongoing.

Helminth infection

Parasitic helminth infection induces production of IgE, which is regarded as an important immune effector mechanism against helminth infection. There is, therefore, a theoretical possibility that treatment with omalizumab could increase susceptibility to helminth infection. The risk of parasitic

### TABLE 4

| Adverse event                        | Omalizumab | Control | P value |
|--------------------------------------|------------|---------|---------|
| Subjects n                           | 3678       | 2452    |         |
| Any adverse event                   | 74.8       | 75.2    |         |
| Upper respiratory tract infection    | 15.7       | 15.7    |         |
| Headache                            | 15.5       | 15.6    |         |
| Nasopharyngitis                      | 14.4       | 15.9    |         |
| Sinusitis                            | 10.1       | 12.0    |         |
| Pharyngolaryngeal pain              | 6.4        | 6.0     |         |
| Cough                               | 5.9        | 7.1     |         |
| Bronchitis                           | 5.2        | 5.6     |         |
| Influenza                            | 5.0        | 6.6     |         |

Data are presented as %, unless otherwise stated. *: ≥5% in any group.

### TABLE 5

| Adverse event                        | Omalizumab | Control | P value |
|--------------------------------------|------------|---------|---------|
| Subjects n                           | 3678       | 2452    |         |
| Any severe adverse event             | 10.8       | 12.6    |         |
| Headache                            | 1.5        | 1.6     |         |
| Upper respiratory tract infection    | 0.7        | 0.6     |         |
| Sinusitis                            | 0.5        | 1.0     |         |
| Influenza                            | 0.3        | 0.7     |         |
| Nasopharyngitis                      | 0.2        | 0.5     |         |

Data are presented as %, unless otherwise stated. *: >0.5% in any group.
infection was investigated in a 52-week, randomised, double-blind, placebo-controlled study in 137 adults and adolescents with allergic asthma or allergic rhinitis at high risk of intestinal helminth infection [22]. The trial showed a slight numerical increase in infection incidence with omalizumab (50 versus 41%) that was not statistically significant. Importantly, course, severity and clinical outcome were unaltered. Caution may be warranted in patients at high risk of helminth infection, in particular when travelling to areas where helminthic infections are endemic (EU SmPC).

**Thrombocytopenia**
Reduced platelet counts were observed in juvenile cynomolgus monkeys receiving omalizumab at doses 3.7-20-fold greater than the highest dose recommended in humans. This observation was made after initiation of the phase-III clinical trials and led to the implementation of increased surveillance of platelet counts in all ongoing and subsequent clinical studies. In all completed studies, there was no evidence of a clinically relevant impact on platelet count during omalizumab treatment. Additional platelet testing is not a requirement of the USA or EU label for omalizumab.

**CONCLUSIONS**
The data derived from the extensive omalizumab clinical trial programme indicate that add-on omalizumab is effective (reducing exacerbations, emergency visits and hospitalisations, and improving quality of life) and well tolerated. Omalizumab addresses an unmet medical need in patients with severe persistent allergic asthma whose symptoms persist despite receiving high-dose inhaled corticosteroids and long-acting β2-agonists, allowing these patients to live beyond the limitations of their asthma.

**REFERENCES**
1 Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. *Allergy* 2005; 60: 309–316.
2 Global Initiative for Asthma. Global strategy for asthma management and prevention. NIH Publication No 02-3659. Bethesda, National Institutes of Health/National Heart, Lung, and Blood Institute, 2005.
3 Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. *Allergy* 2005; 60: 302–308.
4 Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. *Eur Respir J* 2001; 18: 254–261.
5 Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. *Am J Respir Crit Care Med* 2003; 167: 771–778.
6 Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. *Eur Respir J* 2002; 20: 73–78.
7 Busch W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. *J Allergy Clin Immunol* 2001; 108: 184–190.
8 Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. *Allergy* 2004; 59: 709–717.
9 Holgate ST, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. *Clin Exp Allergy* 2004; 34: 632–638.
10 Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. *Allergy* 2004; 59: 701–708.
11 Genentech, Inc. A multicenter, randomized, controlled, open-label study to evaluate the safety of Xolair™ in moderate to severe persistent asthma subjects already treated with other therapies (ALTO). http://clinicalstudyresults.gene.com/q2143g.pdf Date last updated: November 2002. Date last accessed: May 2007.
12 Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. *Thorax* 1992; 47: 76–83.
13 Humbert M, Ayre G, Fox H, Blogg M. Number needed to treat to prevent one medically significant event per year with add-on omalizumab: INNOVATE. XXV EAACI Congress (Vienna, 10–14 June 2006) Abstract Book, 2006; p.41, 125.
14 Chipps B, Buhl R, Beeh KM, Fox H, Thomas K, Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. *Curr Med Res Opin* 2006; 22: 2201–2208.
15 Corren J, Casale T, Lanier BQ, Blogg M, Reisner C, Gupta N. Omalizumab is well tolerated in adolescent/adult patients (≥12 years) with moderate-to-severe persistent asthma. *J Allergy Clin Immunol* 2005; 115: S75.
16 Fernández C, Busse W, Reisner C, Gupta N. Clinical data do not suggest a causal relationship between omalizumab therapy and cancer. *Proc Am Thorac Soc* 2005; 2: A359.
17 Eriksson NE, Holmén L, Högestedt B, Mikoczy Z, Hagmar L. A prospective study of cancer incidence in a cohort examined for allergy. *Allergy* 1995; 50: 718–722.
18 Källén B, Gunnarskog J, Conradson TB. Cancer risk in asthmatic subjects selected from hospital discharge registry. *Eur Respir J* 1993; 6: 694–697.
19 McWhorter WP. Allergy and risk of cancer. A prospective study using NHANESI followup data. *Cancer* 1988; 62: 451–455.
20 Mills PK, Beeson WL, Fraser GE, Phillips RL. Allergy and cancer: organ site-specific results from the Adventist Health Study. *Am J Epidemiol* 1992; 136: 287–295.
21 Vesterinen E, Pukkala E, Timonen T, Aromaa A. Cancer incidence among 78,000 asthmatic patients. *Int J Epidemiol* 1993; 22: 976–982.
22 Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. *Clin Exp Allergy* 2007; 37: 197–207.